Abstract
BackgroundTo evaluate the expression and differential diagnostic significance of CK19, TG, Ki67 and galectin-3 in papillary thyroid carcinoma (PTC) (metastatic and non metastatic), follicular adenoma and nodular goiter in patients from the northeastern part of China.Methods441 PTC specimens and 151 other benign thyroid specimens (97 cases of nodular goiter, 54 cases of nonmalignant follicular adenoma) were collected. Immunohistochemistry for CK19, TG, Ki67 and galectin-3 was performed.ResultsCK19, TG, Ki67 and galectin-3 expression was 96.37% (425/441), 82.77% (365/441), and 40.59% (179/441), 96.82% (427/441), respectively, for the PTC group and the expression of these markers in the benign thyroid lesions group was 25.83% (39/151), 79.47% (120/151), and 37.09% (56/151), 50.99% (77/151), respectively. The expression of CK19 and galectin-3 in PTC was much higher than that in the nonmalignant group (p < 0.05). However, the expression of TG, Ki67 did not differ among these two groups (p > 0.05). The diagnostic efficiency of CK19 and galectin-3 for PTC was 96.37% (537/592) and 84.63% (501/592). CK19 and galectin-3 expression rate in PTC was higher than that in benign disease cases.ConclusionsThe diagnostic efficiency of CK19 for PTC was slightly better than galectin-3. The utilization of these markers combined with morphologic evaluation may be helpful in the differential diagnosis of papillary thyroid carcinoma in the northeastern region of China.
Highlights
To evaluate the expression and differential diagnostic significance of CK19, TG, Ki67 and galectin-3 in papillary thyroid carcinoma (PTC), follicular adenoma and nodular goiter in patients from the northeastern part of China
Immunohistochemistry results In order to evaluate the diagnostic significance of CK19, TG, Ki67 and galectin-3 expression in the distinction of PTC from benign thyroid lesions, we detected these markers expression by using immunohistochemistry
CK19 and Galectin-3 expression did not differ among nodular goiter and follicular adenoma or PTC with lymphatic metastasis and PTC without lymphatic metastasis
Summary
Immunohistochemistry results In order to evaluate the diagnostic significance of CK19, TG, Ki67 and galectin-3 expression in the distinction of PTC from benign thyroid lesions, we detected these markers expression by using immunohistochemistry. We analyzed CK19 and Galectin-3 expression in PTC with or without lymphatic metastasis and different benign thyroid lesions. CK19 positive rate in these four groups was 26.80% (nodular goiter), 24.08% (follicular adenoma), 99.20% (papillary thyroid carcinoma without lymphatic metastasis) and 92.74% (papillary thyroid carcinoma with lymphatic metastasis), respectively. CK19 and Galectin-3 expression did not differ among nodular goiter and follicular adenoma or PTC with lymphatic metastasis and PTC without lymphatic metastasis. There was significant difference in CK19 and Galectin-3 expression between nodular goiter (or follicular adenoma) and PTC with lymphatic metastasis (or PTC without lymphatic metastasis), P < 0.05.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
